Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-05-08
2008-12-30
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S247000, C514S252020, C514S252030, C514S252040, C514S252050
Reexamination Certificate
active
07470687
ABSTRACT:
Aryl oxime derivatives of the formula (I), in which R1, R2, R3, X and B are as defined in Claim1, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.
REFERENCES:
patent: WO 98/06704 (1998-02-01), None
patent: WO 99/65880 (1999-12-01), None
Cecil Textbook of Medicine (20th Edition, vol. 2, 1996, pp. 1739-1747).
Beier Norbert
Eggenweiler Hans-Michael
Schelling Pierre
Wolf Michael
Habte Kahsay T
Merck Patent GmbH
Millen White Zelano & Branigan P.C.
LandOfFree
Aryl oximes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl oximes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl oximes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4045836